文献速递类风湿关节炎

COBRA-light与COBRA方案治疗早期类风湿关节炎的成本效用分析:COBRA-light试验

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial.
PubMed 文献 · RMD Open · 2017-10-25

本研究基于开放标签随机非劣效性COBRA-light试验,对164例早期类风湿关节炎患者进行经济学评价,比较COBRA-light与COBRA方案的成本效用。结果显示,基线分析中两种策略的QALYs相似,COBRA-light成本较高但差异不显著;符合方案分析中COBRA-light成本显著更高。结论认为在低疾病活动度下启动依那西普需更好论证。

要点

  • COBRA-light与COBRA在52周临床结局上非劣效。
  • 基线分析中两组QALYs相似,成本差异不显著。
  • 符合方案分析中COBRA-light成本显著更高。

核心结论

  • 基线成本效用分析中,COBRA-light与COBRA策略产生相似QALYs且成本差异不显著。
  • 若严格按方案执行,COBRA-light因额外依那西普费用可能成本更高而健康获益有限。
  • 在低疾病活动度下启动依那西普的额外获益有限且成本高,需更好论证。

研究设计与样本

  • 基于开放标签、随机、非劣效性COBRA-light试验的经济学评价,纳入164例早期RA患者。
  • COBRA或COBRA-light无应答者接受依那西普50 mg/周,持续3-6个月。
  • 采用社会视角分析,纳入医疗直接、非医疗直接和间接成本,通过患者成本日记测量52周随访期成本。
  • 使用Bootstrapping技术估计成本效果比的不确定性,并以成本效果平面呈现。

主要发现

  • 第52周时,COBRA-light在所有临床结局指标上非劣效于COBRA。
  • 基线成本效用分析(意向性治疗分析)显示COBRA-light更贵(k€9.3,SD 0.9)对比COBRA(k€7.2,SD 0.8),但成本差异不显著(k€2.0;95% CI -0.3至4.4)。
  • 两种策略产生相似的QALYs,敏感性分析显示结果稳健。
  • 符合方案敏感性分析中,假设依那西普按方案规定提供,两组成本均更高:COBRA-light k€11.5(8.3)对比COBRA k€8.5(6.8),成本差异显著(k€2.9;0.6至5.3)。

关键数值与推荐

  • 非劣效性在52周所有临床结局指标上成立。
  • 基线分析成本差异:k€2.0(95% CI -0.3至4.4),不显著。
  • 符合方案分析成本差异:k€2.9(95% CI 0.6至5.3),显著。

临床怎么用

  • 在早期RA中,COBRA-light与COBRA临床疗效非劣效,但COBRA-light因依那西普使用可能增加成本。
  • 对于低疾病活动度患者,启动依那西普需权衡有限健康获益与高成本。
  • 临床决策应结合成本效用信息,并确保按方案执行以控制费用。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate if COmbinatie therapie Bij Reumatoïde Artritis (COBRA)-light therapy is cost-effective in treating patients with early rheumatoid arthritis (RA) compared with COBRA therapy. METHODS: This economic evaluation was performed next to the open-label, randomised non-inferiority COBRA-light trial in 164 patients with early RA. Non-responders to COBRA or COBRA-light received etanercept (50 mg/week) for 3-6 months. The societal perspective analysis took medical direct, non-medical direct and indirect costs into account. Costs were measured with patient cost diaries for the follow-up period of 52 weeks. Bootstrapping techniques estimated uncertainty around the cost-effectiveness ratios, presented in cost-effectiveness planes. RESULTS: 164 patients were randomised to either COBRA or COBRA-light strategy. At week 52, COBRA-light proved to be non-inferior to COBRA therapy on all clinical outcome measures. The results of the base-case cost-utility analysis (intention-to-treat analyses) revealed that COBRA-light strategy is more expensive (k€9.3 (SD 0.9) compared with COBRA (k€7.2 (SD 0.8)), but the difference in costs were not significant (k€2.0; 95% CI -0.3 to 4.4). Also, both strategies produced similar quality-adjusted life-years (QALYs). The sensitivity analyses showed robustness of these results. In a per-protocol sensitivity analysis, in which costs of etanercept were assumed to be provided as prescribed according to protocol, both arms had much higher costs: COBRA-light: k€11.5 (8.3) compared with k€8.5 (6.8) for COBRA, and the difference in costs was significant (k€2.9; 0.6 to 5.3). CONCLUSIONS: In the base-case cost-utility analysis, the two strategies produced similar QALYs for similar costs. But it is anticipated that if protocol had been followed correctly, the COBRA-light strategy would have been more costly due to additional etanercept costs, for a limited health gain. Given the limited added benefit and high costs of starting etanercept in the presence of low disease activity in our trial, such a strategy needs better justification than is available now. TRIAL REGISTRATION NUMBER: 55552928, Results.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Ter Wee MM, Coupé VM, den Uyl D, et al. Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial. RMD Open. 2017. PMID: 29119006. doi:10.1136/rmdopen-2017-000502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。